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Edited by Lukas HuberAbstract The erythrocyte membrane cytoskeleton is organized
as a polygonal spectrin network linked to short actin ﬁlaments
that are capped by adducin at the barbed ends. We have
constructed a mouse strain deﬁcient in b-adducin having
abnormal erythrocytes. We show here that the levels of several
skeletal proteins from b-adducin mutant erythrocytes are
altered. In fact, CapZ, the main muscle actin-capping protein
of the barbed ends that in the erythrocytes is cytoplasmic, is 9-
fold upregulated in mutant skeletons of erythrocytes suggesting a
compensatory mechanism. We also detected upregulation of
tropomodulin and downregulation of a-tropomyosin and actin. In
addition, puriﬁed adducin can be re-incorporated into adducin-
deﬁcient ghosts.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.1. Introduction
The erythrocyte membrane skeleton is a dynamic network of
proteins associated with the plasma membrane. The main
components are spectrin and actin that are organized as a po-
lygonal spectrin network linked to short actin ﬁlaments. The
spectrin–actin junctions contain a group of proteins that pro-
mote andmodulate spectrin–actin interactions, formmembrane
associations, and regulate the actin ﬁlament length. This group
includes adducin, tropomodulin (Tmod), tropomyosin (TM),
protein 4.1 and dematin [1]. The barbed ends of actin ﬁlaments
are capped by adducin in erythrocytes [2]. The pointed ends are
capped by Tmod [3], while TM stabilizes actin ﬁlaments [3–7].
In the muscle, the control of actin ﬁlament growth at the
barbed ends is achieved by the actin capping protein (CapZ)
[8,9] and erythrocytes contain a cytosolic form of CapZ (EcapZ)
[10]. Surprisingly, adducin is the erythrocyte actin capping
protein despite having a 20–100-fold lower aﬃnity than ECapZ
(Kcap Add  100 nM vs Kcap EcapZ  1–5 nM) [2,10].
The adducin protein family is composed of 3 members en-
coded by closely related genes: a-, b- and c-adducin [11,12].
Adducin is present in human erythrocytes as a mixture of a=b
heterodimers and heterotetramers [13], whereas the c-subunit* Corresponding author. Fax: +39-040-2265 55.
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doi:10.1016/j.febslet.2004.08.057is also found at low levels in mouse red cells [14,15] and
combinations of a=b and a=c oligomers are found in other
cells [11,13]. Adducin function is modulated by phosphoryla-
tion of several kinases (Rho kinase, PKA, PKC and casein
kinase II (CKII)) in diﬀerent sites [16–22]. Mice bearing a
targeted mutation in the b-adducin gene develop mild spher-
ocytic hereditary elliptocytosis (SphHE) [14,15] in addition to
hypertension [23].
SphHE is a phenotypical hybrid of mild hereditary ellipto-
cytosis and hereditary spherocytosis: red cells are osmotically
fragile, elliptocytes are less pronounced and somewhat roun-
ded, but no poikilocytes or fragmented forms are present [24].
Some patients presented mutations in b-spectrin [25] and
protein 4.1 deﬁciency [26,27], but the molecular basis is poorly
understood. Therefore, further dissection of the SphHE mo-
lecular pathology was needed and the presence of red cell
abnormalities in the b-adducin deﬁcient mice similar to those
found in SphHE patients highlights the importance of adducin
in the maintenance of the shape and mechanical properties of
the erythrocyte membrane skeleton. On the other hand, it
raises the possibility that compensatory mechanisms might be
activated by the absence of the b-adducin subunit, preventing
the manifestation of a more severe phenotype in the KO
mice.
In this report, we have analyzed the molecular changes
present in the membrane CK of erythrocytes triggered by the
absence of b-adducin in mice.2. Materials and methods
2.1. Mice and antibodies
b-Adducin deﬁcient mice having C57Bl/6 genetic background and
the anti a- and b-adducin antibodies have been described previously
[15]. To transfer the b-adducin gene mutation to a C3H genetic
background, the mutant mice were backcrossed with C3H mice
(Harlan, Italy) for six additional generations. Monoclonal antibodies
anti-CapZ-a and -b (5B12.3 and 3F2.3, respectively) and anti-a-TM
(CH1) were from Developmental Studies Hybridoma Bank at the
University of Iowa. The CH1 monoclonal antibody was generated
using adult heart TM (mainly a-TM isoform) as antigen [28]. Anti
protein 4.1 was a gift from Dirk Hofer, Anatom. Institut, Wurzburg,
Germany, anti-p55 (sc-13603) and anti-Tmod (sc-19206) were from
Santa Cruz Biotechnology, anti-dematin (D77620) was from BD
Transduction Laboratories, and anti-actin (A2066) was from Sigma.
2.2. Preparation of ghosts and skeletal proteins and Western blot
analysis
Regarding the experiments described in Fig. 1, skeletal fractions
were prepared as previously described in the absence of Mg2þ [15].blished by Elsevier B.V. All rights reserved.
Fig. 1. Mutant erythrocytes have an increase in erythrocyte actin capping protein EcapZ-a and -b, and a decrease in a-TM levels. Panel A. Control
(lane 1) and mutant (lane 2) erythrocyte membrane cytoskeleton (80 lg) were separated by SDS–PAGE (8%) and coomassie blue stained. The black
arrows indicate proteins that show diﬀerent levels between control and mutant preparations. The asterisks correspond to degradation products of
higher molecular weight proteins. The band corresponding to actin is indicated. A 14% decrease in actin levels was observed in the extracts form
mutant erythrocytes. Molecular weight markers are indicated on the left as black bars (175, 83, 62, 47.5, 32.5 and 25 kDa from top to bottom). Panel
B. The same extracts from Panel A were analyzed in a silver stained 2D gels. The acidic and basic sides are indicated by the symbols ‘‘+’’ and ‘‘)’’,
respectively. a-TM, EcapZ-a and EcapZ-b spots are indicated by arrows. Panel C. Western blot analyses were performed using anti a-TM, anti
EcapZ-a and anti EcapZ-b antibodies. +/+ and )/) depict wild type and b-adducin deﬁcient mice, respectively, of the same extracts utilized in Panel
A. The same extracts used in Panel A were used for the Western Blot analysis and the same amount of protein was loaded for +/+ and )/) extracts.
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fractions were prepared in the presence of Mg2þ as described [29].
Brieﬂy, red cells were separated from freshly drawn blood anticoagu-
lated with acid citrate-dextrose by sedimentation at 1·g through 4
volumes of sedimentation buﬀer [150 mM NaCl, 5 mM sodium
phosphate, pH 7.5, and 0.75% (w/v) Dextrane 500-Pharmacia] at 4 C.
Erythrocytes were then washed three times with 4–10 volumes of PBS
(10 mM sodium phosphate pH 7.5, 150 mM NaCl) and centrifuged at
6000 rpm. Pellets were resuspended in lysis buﬀer (5 mM sodium
phosphate, pH 8, 1 mM DTT, 40 lg/ll PMSF and protease inhibitors
cocktail, Roche) containing or not 2 mMMgCl2 and frozen at )80 C.
The lyzed cells were frozen/thawed twice in dry-ice and cold water and
centrifuged at 40 000·g for 10 min in a Ti60-rotor. The cytoplasmic
fractions were separated and stored at )80 C, while the pellets were
washed three times with cold lysis buﬀer (with or without MgCl2) and
centrifuged at 40 000·g. The ﬁnal ghost pellets were resuspended in the
same buﬀer at 1/15 of starting volume, brieﬂy sonicated (3 · 10 s) and
stored at )80 C. For skeletal preparations, the ghost fractions were
resuspended with Triton X-100-containing solution (10 mM Tris–HCl,
pH 8, 100 mM NaCl, 1 mM EDTA, 2 mM DTT, protease inhibitors
containing or not 2 mM MgCl2, and 0.5% v/v Triton-X-100) and
centrifuged for 40 min at 16 000 rpm. The pellet was resuspended again
in the Triton X-100-containing solution and centrifuged for 50 min at
16000 rpm. The ﬁnal pellet (skeletons) was resuspended in the same
solution without Triton X-100. The protein concentration of cyto-
plasmic and ghost fractions was measured by triplicate by using the
Bradford method (Bio-Rad) and analyzed by SDS–PAGE followed by
Coomassie blue staining.
Analysis of the ghosts proteins by Western blot was performed as
previously described [15]. The gel images were acquired with the
VersaDoc Imaging System (Bio-Rad) and bands (or spots) quantiﬁed
with the help of the Quantity One or PDQUEST software (Bio-Rad).
2.3. 2D gels and mass spectrometry analysis
The protein extracts were precipitated in acetone:tributylphos-
phate:methanol (1:12:1) as described [30]. The pellets were resuspended
in 2D buﬀer (7 M urea, 2 M thiourea, 2% CHAPS, 4 mM tributyi-
phosphine and protease inhibitor cocktail). The ﬁrst dimension was
performed by loading 150–300 lg of protein extract into IPG stripswith diﬀerent pH ranges (3–10, 3–6, 4–7 and 5–8; strips were 17 cm
long). The Protean IEF (Bio-Rad) cell was used following the protocol
described by the manufacturer. Gradient (8–15%) or non-gradient
(12%) SDS–PAGE were used for the second dimension.
The selected bands and spots (from the SDS–PAGE and 2D gels,
respectively) were extracted from the acrylamide after digestion with
trypsin (Promega). The digestion products were separated by micro-
high pressure liquid chromatography and analyzed by electrospray
ionization mass spectrometry (Finnigan LCQ DECA, Thermo-Fin-
ningan Corp., San Jose, CA). The obtained data were analyzed with
MASCOT (Matrix Science) and SWISSPROT software.
2.4. Preparation of puriﬁed adducin and complementation assay of
mutant ghosts
HPLC-puriﬁed human erythrocyte adducin was prepared as previ-
ously described [13,29,31]. The binding assay of mutant ghosts with
HPLC-puriﬁed human adducin was performed as described [10] with
minimal modiﬁcations. Brieﬂy, ghosts from b-adducin deﬁcient ery-
throcytes (20 lg) were incubated with increasing amounts of HPLC-
puriﬁed human adducin (0.7, 1.4 and 2.8 lg) for 30 min at 0 C.
Control reactions were performed by omitting ghosts and adding 20 lg
of BSA or by omitting puriﬁed adducin. The soluble fraction was
separated from the membrane-associated skeletons by centrifugation
through a sucrose cushion. The pellets were electrophoresed on 10%
SDS–PAGE and blotted onto a PVDF membrane.3. Results
3.1. Erythrocyte skeletons of mutant mice have increased levels
of EcapZ and decreased levels of a-TM
Erythrocyte cytoskeletal protein preparations of control and
b-adducin deﬁcient mice showed evident diﬀerences in at least
four bands of apparent MW of 65 and 30–32 kDa observed
only in control mice and 38 and 34 kDa present only in mutant
mice (see Muro et al. [15] and Fig. 1A). Two-dimensional gels
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kDa (having an approximated pI of 5.4 and 5.7, respectively)
that were visible only in the preparation from mutant mice
(Fig. 1B). Mass spectrometry analysis indicated that they were
the EcapZ-a and EcapZ-b subunits, respectively. Another spot
of approximate pI 4.6 having a relative MW of 30 kDa was
visible only in the wild type 2D gel. Mass spectrometry analysis
identiﬁed this spot as a-TM (Fig. 1A and B).
Western blot analysis with antibodies against both subunits
of EcapZ showed a 9-fold increase of both proteins in the
skeletal fractions of mutant animals (Fig. 1C) conﬁrming our
observations in the SDS–PAGE gels, 2D gels and mass spec-
trometry, while we observed a 40–50% reduction in the mutant
mice using an antibody against a-TM (Fig. 1C).
The 65 kDa band is probably a degradation product of b-
adducin as diverse b-adducin peptides were detected by mass
spectrometry. The other bands showing diﬀerences between
control and mutant preparations (Fig. 1A, 55 and 83 kDa of
MW, indicated by asterisks) are probably degradation prod-
ucts of high molecular weight proteins as mass spectrometry
analysis revealed mostly the presence of a- and b-spectrin, or
protein 4.1 peptides (data not shown). We were unable to
identify in the 2D gels the 55, 65 and 83 kDa bands marked
with the arrow and asterisks in Fig. 1A.
3.2. Altered levels in other major components of the RBC
membrane cytoskeleton from b-adducin deﬁcient mice
To determine variations in other erythrocyte skeletal pro-
teins not evidenced by the SDS–PAGE or the 2D analysis, we
performed a Western blot analysis using a set of antibodies
directed against the main actin-associated proteins.
The protein extracts were prepared using a protocol that
contained 2 mM Mg2þ that was diﬀerent to the one used in
Fig. 1 (without Mg2þ). This change was aimed to obtain a
higher stability in the actin ﬁlaments (see Section 2 and [10]).
In fact, the levels of some of the actin-associated proteins are
reduced in ghosts prepared in the absence of Mg2þ in com-
parison to Mg2þ-ghosts indicating a skeleton-stabilizing role of
Mg2þ during protein preparation [10].
In addition to the variations in EcapZ and a-TM (not
shown), we observed changes in Tmod, dematin and actin
levels. A mean decrease of 74% in the levels of a-adducin, a
65% decrease in a-TM levels and 9-fold increase in EcapZ-bFig. 2. Diﬀerences in the levels of other major skeletal proteins are
observed in erythrocyte skeletal preparations of mutant mice. Western
blot analysis of erythrocyte skeletal protein preparations of control
(‘‘+/+’’, lane 1) and mutant mice (‘‘)/)’’, lane 2) using a set of anti-
bodies directed against cytoskeletal proteins (indicated on the left).levels in the skeleton mutant extracts preparations were ob-
served (Fig. 2 and Table 1). We conﬁrmed the previously re-
ported trend of 15% decrease in the actin levels in the
cytoskeletal preparations of mutant erythrocytes [15] (Fig. 2
and Table 1). We were not able to detect in the Western blot
analysis the appearance of smaller extra bands in the mutant
extracts indicating that the decrease in a-TM and actin could
be the consequence of increased proteolytic degradation. To
verify whether the observed diﬀerences were dependent on the
genetic background of the mice, we performed protein prep-
arations from erythrocytes of control and b-adducin deﬁcient
mice having a C3H genetic background. We observed similar
results to those presented in Fig. 2 and Table 1 in preparations
from mice with a C3H genetic background (not shown).
Western blot analysis using an anti-Tmod antibody showed
a 65% increase in Tmod levels in the mutant preparation
(Fig. 2 and Table 1). Dematin showed a minor decrease in the
mutant preparations of the main lower band intensity and a
79% increase in the upper band intensity (Fig. 2 and Table 1).
The levels of other cytoskeletal protein (protein 4.1 and p55)
showed no signiﬁcant diﬀerences between wild type and KO
mice by Western blot analysis (Fig. 2 and Table 1).
No variations were observed in the cytoplasmic levels of a-
and b-EcapZ (data not shown). In addition, we were neither
able to detect Tmod and a-TM in cytoplasmic preparations
from control animals, as reported previously by another group
[10], nor from mutant preparations.
3.3. Puriﬁed adducin is incorporated into adducin-deﬁcient
ghosts
To determine whether puriﬁed adducin (as a=b heterodimer)
was able to be incorporated into cytoskeletons from b-addu-
cin-deﬁcient mice to eventually replace EcapZ we performed a
binding assay utilizing ghosts from KO mice and puriﬁed
human erythrocyte adducin.
Fig. 3 shows the Western blot analysis of both b-adducin
and EcapZ-b after incubation of a ﬁxed amount of mutant
ghosts with increasing amounts of puriﬁed adducin. We ob-
served that b-adducin was incorporated into adducin-deﬁcient
ghosts in a dose-dependent manner (Fig. 3, lanes 2–4). The a-
adducin subunit was incorporated in a similar manner to the b-Fig. 3. Puriﬁed adducin can be incorporated into adducin-deﬁcient
ghosts in vitro. Ghosts from mutant mice were incubated with in-
creasing amounts of puriﬁed adducin (0.7, 1.4 and 2.8 lg in lanes 2, 3
and 4, respectively) and the membrane-skeleton (pellet) was separated
from the soluble fraction through a sucrose cushion. b-Adducin and
EcapZ-b protein levels were detected by Western blot analysis. Lane 1
contains 2.8 lg of adducin plus 20 lg of BSA. Lanes 5 and 6 contain
20 lg of mutant and control ghosts protein preparations, respectively,
that underwent the same experimental procedure as the other lanes.
Quantiﬁcation of the bands showed an increase of b-adducin and a
decrease of EcapZ-b (relative values of b-adducin: 8, 91, 111, 131, 0
and 100 for lanes 1–6, respectively; relative values of EcapZ-b: 0, 1280,
1069, 985, 1210 and 100 for lanes 1 to 6, respectively; ratio b-adducin/
EcapZ-b: 7.1, 10.5 and 13.5 for lanes 2–4, respectively).
Table 1
Altered levels of cytoskeletal proteins in RBC from mutant mice
Band # Protein Conﬁrmed by mass spectrometry/WB Levels in +/+ mice Levels in )/) mice P value
1 b-Adducin No/Yes 100a ND NA
2 a-Adducin No/Yes 100 6 26 6 6 0.01
3 EcapZ-a Yes/Yes ND 100a NA
4 EcapZ-b Yes/Yes 100 20 880 153 6 0.01
5 a-TM Yes/Yes 100 12 35 9 6 0.01
6 Actin No/Yes 100 2 83 8 6 0.01
7 Tropomodulin No/Yes 100 13 165 5 6 0.05
8a Dematin 52 kDa No/Yes 100 8 179 20 <0.05
8b Dematin 48 kDa No/Yes 100 3 94 4 NS
9 P55 No/Yes 100 2 105 7 NS
10 Protein 4.1 No/Yes 100 9 91 11 NS
The levels of the various cytoskeletal proteins shown in Fig. 2 were quantiﬁed as described in Section 2. The numbers indicate relative amounts of
each protein in cytoskeleton extracts relative to those found in those control extract (S.D.). ‘‘WB’’ stands for western blot. ND, not detected; NA,
not applicable; NS, non signiﬁcant.
aAn arbitrary value of 100 was given as no signal was detected in mutant and control mice, in the case of b-adducin and EcapZ-a, respectively. P-
value was calculated using the Student t test.
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bation of mutant ghosts with increasing amounts of adducin
(Fig. 3, lanes 2–4). The control lane conﬁrmed that the puriﬁed
adducin did not auto-precipitate (Fig. 3, lane 1) as it included
the maximum amount of adducin used in lane 4 (2.8 lg) plus
an amount of BSA similar to that of ghosts used in the other
lanes (20 lg). Quantiﬁcation of the bands indicated that the
ratio between adducin and EcapZ increases with the addition
of higher amounts of adducin supporting the idea that the
incorporation of EcapZ is a compensatory mechanism trig-
gered by the absence of b-adducin.4. Discussion
The b-adducin deﬁcient mice showed a decrease of the a-
adducin levels and an up regulation of the c-subunit in RBC
skeletons [14,15]. These adaptations seem not to be suﬃcient
to attain normal erythrocyte function, since b-adducin KO
mice have increased erythrocyte fragility and suﬀer from mild
compensated hemolytic anemia [14,15]. We showed now that
the levels of some of the actin-associated proteins in mutant
mice erythrocytes are diﬀerent from those found in control
animals, suggesting that both the actin ﬁlament-complex and
actin polymerization activity might be altered.
As previously mentioned, the main capping protein of the
actin-ﬁlament barbed ends in the muscle is CapZ, while in
erythrocyte membrane skeletons this function is performed by
adducin [2] and EcapZ remains in the cytoplasm [10]. The
aﬃnity of adducin and EcapZ for the actin ﬁlaments has been
determined in vitro by Dr. Velia Fowler’s group using puri-
ﬁed proteins [2,3,10]. The fact that adducin is the erythrocyte
actin capping protein notwithstanding its lower Kcap respect
to that of EcapZ strongly suggests that the in vivo aﬃnity is
not all and may be other proteins might cooperate in the
stabilization of the binding of adducin to the actin-ﬁlaments
barbed ends [10] as already observed in the case of spectrin–
actin complexes [32,33]. In spite of this, we did not observe a
complete displacement of EcapZ in the mutant ghosts by
exogenously added adducin but increasing amounts of ad-
ducin produced a reproducible minor decrease in the EcapZ
levels in the ghosts fraction (23% decrease in lane 4 of Fig. 3).
Obviously, this is not an in vivo experiment and is far from
what really occurs during erythropoiesis, when the cytoskel-eton takes its ﬁnal structure and proteins are synthesized si-
multaneously and have to compete for a place in the skeleton
structure.
However, the increase of the EcapZ levels in the cytoskele-
ton of mutant erythrocytes did not fully compensate for the
absence of b-adducin: variations in a-TM, Tmod and actin,
and changes in a- and c-adducin were observed. Consequently,
mice have a change in the shape and mechanical properties of
red cells and suﬀer from mild hemolytic anemia [14,15].
The binding of Tmod to the actin ﬁlaments pointed ends is
stabilized by TM [34]. The increase in Tmod levels together
with the decrease in a-TM and actin suggest that the in vivo
interaction among actin, Tmod and TM might be also aﬀected
in mutant erythrocytes. In addition, the important decrease in
the levels of a-TM in mutant preparations might suggest a new
role for adducin in stabilizing a-TM within the actin ﬁlament-
complex of erythrocytes. In the case of the targeted inactiva-
tion in mice of other erythrocyte protein, the anion transporter
Band 3 (AE1), it was shown that the close interaction of AE1
with glycophorin A (GPA) during their biosynthesis as the
AE1-deﬁcient erythrocytes were devoid of GPA [35]. One
possible hypothesis could be that, similarly to that proposed
for Band 3, adducin (or other adducin partner disturbed in the
erythrocyte skeletons from mutant mice) might play a ‘‘chap-
eron-like’’ role in the formation of actin ﬁlaments, aﬀecting the
levels of a-TM and Tmod, a task that seems not to be correctly
performed by EcapZ. On the other hand, the absence of
variations in p55 and protein 4.1 might suggest that direct or
indirect interactions of adducin with p55 and protein 4.1 are
limited.
We have shown here that erythrocytes skeletons from
b-adducin deﬁcient mice contain a 9–10-fold upregulation of
EcapZ, a 65% decrease in a-TM and an increase in Tmod. This
is neither a consequence of the protocol used to prepare the
protein extract nor due to the genetic background of the mice.
The described molecular defects might generate a reduction in
the number, length and/or stability of the actin ﬁlaments,
probably producing altered junctional complexes that could be
the cause of the presence of SphHE in mutant mice [15].
Acknowledgements: Author acknowledges Corrado Guarnaccia
for help with adducin puriﬁcation, Mauro Sturnega for animal care
and Youhna Ayala for protein sequencing assistance with the mass
spectrometer.
40 F. Porro et al. / FEBS Letters 576 (2004) 36–40References
[1] Bennett, V. and Gilligan, D.M. (1993) Annu. Rev. Cell Biol. 9,
27–66.
[2] Kuhlman, P.A., Hughes, C.A., Bennett, V. and Fowler, V.M.
(1996) J. Biol. Chem. 271, 7986–7991.
[3] Fowler, V.M. (1996) Curr. Opin. Cell Biol. 8, 86–96.
[4] Fowler, V.M. and Bennett, V. (1984) J. Biol. Chem. 259, 5978–
5989.
[5] Shen, B.W., Josephs, R. and Steck, T.L. (1986) J. Cell Biol. 102,
997–1006.
[6] Cooper, J.A. (2002) Curr. Biol. 12, R523–R525.
[7] Ono, S. and Ono, K. (2002) J. Cell Biol. 156, 1065–1076.
[8] Schafer, D.A. and Cooper, J.A. (1995) Annu. Rev. Cell Dev. Biol.
11, 497–518.
[9] Casella, J.F., Craig, S.W., Maack, D.J. and Brown, A.E. (1987)
J. Cell Biol. 105, 371–379.
[10] Kuhlman, P.A. and Fowler, V.M. (1997) Biochemistry 36, 13461–
13472.
[11] Dong, L., Chapline, C., Mousseau, B., Fowler, L., Ramsay, K.,
Stevens, J.L. and Jaken, S. (1995) J. Biol. Chem. 270, 25534–
25540.
[12] Joshi, R., Gilligan, D.M., Otto, E., McLaughlin, T. and Bennett,
V. (1991) J. Cell Biol. 115, 665–675.
[13] Gardner, K. and Bennett, V. (1986) J. Biol. Chem. 261, 1339–1348.
[14] Gilligan, D.M., Lozovatsky, L., Gwynn, B., Brugnara, C.,
Mohandas, N. and Peters, L.L. (1999) Proc. Natl. Acad. Sci.
USA 96, 10717–10722.
[15] Muro, A.F., Marro, M.L., Gajovic, S., Porro, F., Luzzatto, L.
and Baralle, F.E. (2000) Blood 95, 3978–3985.
[16] Shima, T., Okumura, N., Takao, T., Satomi, Y., Yagi, T., Okada,
M. and Nagai, K. (2001) J. Biol. Chem. 276, 42233–42240.
[17] Matsuoka, Y., Li, X. and Bennett, V. (2000) Cell. Mol. Life Sci.
57, 884–895.[18] Fukata, Y., Oshiro, N., Kinoshita, N., Kawano, Y., Matsuoka,
Y., Bennett, V., Matsuura, Y. and Kaibuchi, K. (1999) J. Cell
Biol. 145, 347–361.
[19] Matsuoka, Y., Li, X. and Bennett, V. (1998) J. Cell Biol. 142, 485–
497.
[20] Matsuoka, Y., Hughes, C.A. and Bennett, V. (1996) J. Biol.
Chem. 271, 25157–25166.
[21] Bianchi, G. et al. (1994) Proc. Natl. Acad. Sci. USA 91, 3999–
4003.
[22] Waseem, A. and Palfrey, H.C. (1988) Eur. J. Biochem. 178, 563–
573.
[23] Marro, M.L. et al. (2000) Hypertension 36, 449–453.
[24] Benz, E.J. (1994) in: The Molecular Basis of Blood Diseases
(Stamatoyannopoulos, G., Nienhuis, A.W., Majerus, P. and
Varmus, H., Eds.), pp. 257–292, WB Saunders Company, Phila-
delphia, PA.
[25] Jarolim, P., Wichterle, H., Hanspal, M., Murray, J., Rubin, H.L.
and Palek, J. (1995) Br. J. Haematol. 91, 502–510.
[26] Tchernia, G., Mohandas, N. and Shohet, S.B. (1981) J. Clin.
Invest. 68, 454–460.
[27] Feo, C.J., Fischer, S., Piau, J.P., Grange, M.J. and Tchernia, G.
(1980) Nouv. Rev. Fr. Hematol. 22, 315–325.
[28] Lin, J.J., Chou, C.S. and Lin, J.L. (1985) Hybridoma 4, 223–
242.
[29] Bennett, V. (1983) Methods Enzymol. 96, 313–324.
[30] Mastro, R. and Hall, M. (1999) Anal. Biochem. 273, 313–315.
[31] Joshi, R. and Bennett, V. (1990) J. Biol. Chem. 265, 13130–13136.
[32] Gardner, K. and Bennett, V. (1987) Nature 328, 359–362.
[33] Mische, S.M., Mooseker, M.S. and Morrow, J.S. (1987) J. Cell
Biol. 105, 2837–2845.
[34] Weber, A., Pennise, C.R., Babcock, G.G. and Fowler, V.M.
(1994) J. Cell Biol. 127, 1627–1635.
[35] Hassoun, H., Hanada, T., Lutchman, M., Sahr, K.E., Palek, J.,
Hanspal, M. and Chishti, A.H. (1998) Blood 91, 2146–2151.
